Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 0,77 M
EBIT 2016 -14,1 M
Net income 2016 -11,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,00 M
EBIT 2017 -11,9 M
Net income 2017 -9,44 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 18,6x
Capi. / Sales2017 7,16x
Capitalization 14,3 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders.Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism.It also develops... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
03/21 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financi..
03/13 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
03/13 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
03/07 CYCLACEL PHARMACEUTICALS : CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a N..
03/07 Cyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Ca..
02/28 INSIDER TRADING ACTIVITY CYCLACEL PH : CYCC) – Major Shareholder Bought 13..
02/23 CYCLACEL PHARMACEUTICALS : CYCC) Tumbles on Failed Tests
02/23 NETWORKNEWSBREAKS – CYCLACEL P : CYCC) Shares Tumble on Disappointing Phas..
02/23 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
02/23 CYCLACEL PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 108%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%14
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results